United Financial Statements From 2010 to 2025
| UTH Stock | EUR 348.50 9.70 2.86% |
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
United |
United Therapeutics Company Return On Equity Analysis
United Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current United Therapeutics Return On Equity | 0.17 |
Most of United Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, United Therapeutics has a Return On Equity of 0.1661. This is 100.69% lower than that of the Healthcare sector and 100.46% lower than that of the Biotechnology industry. The return on equity for all Germany stocks is 153.58% lower than that of the firm.
United Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining United Therapeutics's current stock value. Our valuation model uses many indicators to compare United Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across United Therapeutics competition to find correlations between indicators driving United Therapeutics's intrinsic value. More Info.United Therapeutics is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.66 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for United Therapeutics is roughly 1.51 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the United Therapeutics' earnings, one of the primary drivers of an investment's value.About United Therapeutics Financial Statements
United Therapeutics stakeholders use historical fundamental indicators, such as United Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in United Therapeutics' assets and liabilities are reflected in the revenues and expenses on United Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in United Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Additional Information and Resources on Investing in United Stock
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out the analysis of United Therapeutics Correlation against competitors. For more detail on how to invest in United Stock please use our How to Invest in United Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.